Valeant rolls out prelim data on its newly purchased cancer vaccine Provenge

Valeant ($VRX) only just picked up Provenge from bankrupt Dendreon ($DNDN), but it's already trumpeting positive data for the flailing prostate cancer vaccine. According to preliminary results from a Phase II study, the immune response from Provenge continues two years after certain prostate cancer patients completed treatment. Dendreon exec Andrew Sandler called the data "very encouraging." Report